Palifermin (Kepivance) for myelotoxic-therapy-related mucositis.
Palifermin (Kepivance) is a recombinant keratinocyte growth factor that decreases the incidence and duration of severe oral mucositis (OM) in patients with hematologic malignancies receiving myelotoxic chemotherapy and hematopoietic stem cell support. It appears to be well tolerated and could decrease use of opioid analgesics and total parenteral nutrition in these patients.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects*; D003131:Combined Modality Therapy; D051523:Fibroblast Growth Factor 7; D005346:Fibroblast Growth Factors / Q000627:therapeutic use*; D006801:Humans; D009061:Mouth Mucosa; D016032:Randomized Controlled Trials as Topic; D013280:Stomatitis / Q000628:therapy*; D014916:Whole-Body Irradiation
C496453:FGF7 protein, human; D051523:Fibroblast Growth Factor 7; D005346:Fibroblast Growth Factors